Brief: CohBar Announces Positive Topline Results From Phase 1A/1B Study Of CB4211 Under Development For Nash And Obesity
10/08/2021 22:14
Aug 10 (Reuters) - CohBar Inc CWBR.O :
* COHBAR ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE
1A/1B
STUDY OF CB4211 UNDER DEVELOPMENT FOR NASH AND OBESITY
* COHBAR INC - CB4211 WAS WELL-TOLERATED AND APPEARED SAFE
WITH NO
SERIOUS ADVERSE EVENTS
* COHBAR INC - STUDY MET ITS PRIMARY ENDPOINT
* COHBAR INC - STUDY SHOWED REDUCTION IN GLUCOSE AND TREND
TOWARDS
BODY WEIGHT REDUCTION
Source text for Eikon: ID:nGNX8Z7XT1
Further company coverage: CWBR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CohBar
See all newsBrief: CohBar, Inc. Q2 EPS USD -1.49
Brief: Morphogenesis And CohBar Announce Positive Results From Phase 1B Trial Of IFX-HU2.0 Personalized Cancer Vaccine, In Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) And Cutaneous Squamous Cell Carcinoma (CSCC)
U.S. STOCKS ON THE MOVE-Galecto, Pinterest, Standard Lithium
CohBar surges on merger agreement with Morphogenesis
U.S. STOCKS ON THE MOVE-Chevron, Broadcom, Williams-Sonoma